Final psychopharm Flashcards
Paliperidone
Antipsychotic (Invega sustenna)
Available as a long acting injectable
Active metabolite of risperidone
First generation antipsychotics and risks
TD dystonia akathesia parkinsonism Metabolic-wt gain, dyslipidemia, hyperglycemia
clozapine facts
highly effective antipsychotic risk of several side effects least likely to cause EPS used more for refractory pts- most effective CAN CAUSE AGRANULOCYTOSIS
Olanzapine facts
Very effective antipsychotic
chemical derivative of clozapine
reduced EPS, superior to Haldol
Weight gain
First gen antipsychotics names
Haloperidol chlorpromazine (thorazine)
Big concern and side effect seen with risperidone
elevated prolactin levels
secondary negative symptoms of schizophrenia
Social isolation from paranoia
apathy from depression
neuroleptic induced parkinsonism
First Generation antipsychotic receptors facts
65% occupany of striatal D2 receptors is needed for efficacy
Neuro side effects emerge when there is greater than 80% occupancy
High potency conventional agents (haldol and fluvenazine) are highly selective of D2 so they are more likely to cause EPS (dystonia, akathesia, parkinsonism)
akathesia
extremely distressing motor restlessness primarily in lower extremities
CAN BE MISTAKEN FOR PSYCHOTIC AGITATION
DOSE DEPENDENT
CAN SWITCH TO A MED THAT IS KNOWN FOR LESS AKATHESIA
Propanolol can be helpful for akathesia
WHAT TO DO WITH AKATHESIA
LOWER THE DOSE
POSSIBLE PROPANOLOL
POSSIBLE MIRTAZEPINE (antagonizes serotonin 2A-receptors implicated in pathology of akathesia
Dystonia
sustained muscle spasms (anywhere but often neck, tongue, back)
can occur within the first 4 days
dystonia is rare in atypical antipsychotics like quetiapine and clozapine
antipsychotic induced parkinsonism facts
tremor, stiffness, gait disturbance
diminished facial expression
most common in high potency first gen antipsychotics
elderly concerns with first gen antipsychotics
High risk anticholinergic effects -constipation, dry mouth, blurred vision, urinary retention, memory impairment
TD facts
rarely appears right away (less than 6 mo)
Once occurs may be irreversible
Involuntary, choreiform (quick/nonrythmic) movements of mouth tongue and upper extremities.
also possible dystonic form
lifetime risk 50-60%
Lower dose or switch to clozapine
lowering dose or switching may cause withdrawal dyskinesia that may resolve in 6wks
severe cases-tetrabenzine or deep brain stimulation
neuroleptic malignant syndrome facts
Rare, potential lethal complication
hyperthermia
rigidity, confusion,diaphoresis
elevated CPK, leucocytosis
clozapine facts
tricyclic dibenzodiazepine derivative antipscyhotic
for tx resistant schizophrenia or schizoaffective
tx of SI
binds to all 5 dopamine subtypes, muscarinic, histaminergic, cholinergic, and seritonergic
Also modulates glutamatergic NMDA sensitivity and BDNF
Aripiprazole pharmacodynamics and kinetics facts
Abilify
dihydroquinolinone unrelated to other antipsychotics
approved for schizophrenia and bp mania and mixed
partial agonist of D2-30% activity compared to dopamine
high affinity of 5ht1a partial agonist, full agonist 5ht2A
moderate affinity to alpha adrenergic and histamine
CYP 450 2D6 and 3A4
long half life (up to 94 hrs)
2wks needed to achieve steady level after dose initiation or change
What needs to be done with risperidone and paliperidone? And other concerns?
requires careful titration to avoid EPS
Monitoring of hyperprolactinemia
metabolic syndromes
Which two antipsychotics are known to have the highest metabolic liability?
Clozapine
Olanzapine
clozapine class and action
tricyclic dibenzodiazepine derivative binds to several CNS receptors FDA approved for schizophrenia, schizoaffective, SI peak plasma levels reached in 2 hrs CYP 1A2, 3A4, 2D6
clozapine lab requirements
To initiate clozapine:
wbc’s at least 3500
ANC at least 2000
weekly cbc x 6mo then biweekly for 6 mo, then monthly if they stay stable
additional cardiac and neuro possible side effects with clozapine
myocarditis, cardiomyopathy (0,01-0,2%) present like flu like illness, cp, reduced ejection fraction, elevated CPK, T wave changes
Seizures- 5-10%- usually caused by rapid dose escalation or increased plasma concentrations
Obesity, DM(markedly reduced insulin sensitivity), dyslipidemia
Methylphenidate
IR- behavioral effects peak at 1-2 hrs
Dissipate within 3-5
More rapidly absorbed and peaks sooner than Ritalin(similar pharmacokinetic profile)
equal racemic mixture of d,l-threo-MPH
concerta
racemic mixture of d,l-threo-MPH 50/50 (essentially methylphenidate)- osmotic release oral system (OROS) labeled for 12 hrs of coverage
instead of Methylphenidate 3x daily
focalin
primary active form of MPH d-threo isomer available in immediate and extended release
10mg of MPH is equivalent to 5mg of d-MPH
Daytrana
MPH through the skin via transdermal system
effects within 2 hrs and 3 hrs after removal
doesnt do first pass metabolism so lower doses may be needed than oral doses
Good for pts’ who can’t tolerate PO
Quillivant
AKA MEROS
oral suspension MPH
may be useful for children who cant tolerate pills or experience skin reactions to the patch
Amphetamine forms
dextroamphetamine (dex;dexadrine)
Mixed amphetamine salts (MAS;Adderall)
Lisdexamphetaminedimesylate (Vyvance;LDX)